BONE BIOLOGICS CORP (BBLG) Stock Income Statement
USA - NASDAQ:BBLG - US0980706008 - Common Stock
1.6 USD
-0.1 (-5.88%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | 0 | 0 | 0 | |||
| Gross Profit | null | null | 0 | 0 | 0 | |||
| Operating Expenses | 4.29M | 4.22M | 9.43M | 3.67M | 1.10M | |||
| Research and Development | 2.15M | 2.13M | 6.91M | 1.58M | 80.00K | |||
| Selling, General, and Administrative Expenses | 2.14M | 2.09M | 2.52M | 2.09M | 1.02M | |||
| Operating Income | -4.29M | -4.22M | -9.43M | -3.67M | -1.10M | |||
| Interest Income/Expense | 67.00K | 55.70K | 1.90K | 0 | -810.00K | |||
| Other Income/Expense | 5.30K | 51.10K | 892.70K | 2.18M | 300.00K | |||
| Non Recurring Items | null | 0 | -415.00K | null | null | |||
| Income Before Taxes | -4.22M | -4.11M | -8.95M | -1.48M | -1.61M | |||
| Income Tax | null | null | null | null | 1.60K | |||
| Net Income | -7.43M | -7.32M | -8.95M | -1.48M | -1.61M | |||
| EBITDA | null | undefined | undefined | undefined | undefined | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -21.1387 | -28.9663 | -204.0432 | -186.63 | -511.11 | |||
| Non GAAP EPS | -21.154 | -29.784 | -398.34 | -604.8 | null | |||
| Statistics | ||||||||
All data in USD